The prestigious award was presented during the ESMO Targeted Anticancer Therapies (TAT) 2026 conference in Paris for an international multicenter study involving 50 centers across 17 countries, focusing on antibody-drug conjugates (ADCs) in metastatic urothelial carcinoma. Dr. Rizzo is considered among the most influential researchers in the world, confirmed for the fourth consecutive year in Stanford University’s 'World’s Top 2% Scientists' list (based on 2025 data); with an H-Index of 62 (Scopus data) and nearly 300 publications, he ranks in the global top 1% for Oncology and Carcinogenesis, specializing primarily in uro-oncology.
Celebrating Excellence: Dr. Alessandro Rizzo, Recipient of the Prestigious ESMO Merit Award 2026
